Affinity Asset Advisors, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Affinity Asset Advisors, LLC reported 99 stock positions worth $2.0 billion. Its top holding was Roivant Sciences (ROIV) at 6.6% of the portfolio, followed by Apogee Therapeutics (APGE, 6.5%) and Spyre Therapeutics (SYRE, 5.6%). Compared with Q1 2026, it opened 16 new positions, sold out of 7, added to 32 and reduced 30. The biggest buy was a new position in First Tracks Biotherapeutics (TRAX) and the biggest sale an exit from Centessa Pharmaceuticals (CNTA).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001773195
- Portfolio Value
- $2.0B (Q2 2026)
- SEC Filing
- 0001011438-26-000516 ↗ filed Aug 13, 2026
Holdings Value
Holdings 99 stocks · $2.0B
| ROIV Roivant Sciences Ltd. | 6.60% | 3,750,000 | $132.7M | Add +33.9% |
| APGE Apogee Therapeutics Inc. | 6.51% | 987,000 | $131.0M | Reduce -23.2% |
| SYRE Spyre Therapeutics Inc. | 5.65% | 1,279,134 | $113.6M | No change |
| XENE Xenon Pharmaceuticals Inc. | 4.79% | 1,595,000 | $96.3M | Reduce -4.8% |
| ERAS Erasca Inc. | 4.78% | 5,250,000 | $96.2M | Reduce -1.9% |
| INSM Insmed Inc. | 3.45% | 650,000 | $69.3M | Add +35.4% |
| PRAX Praxis Precision Medicines I | 3.08% | 185,000 | $61.9M | Add +8.8% |
| ALKS Alkermes PLC | 2.93% | 1,125,000 | $58.9M | Reduce -16.7% |
| ORKA Oruka Therapeutics Inc. | 2.79% | 590,000 | $56.2M | Add +18.1% |
| ANAB Anaptysbio Inc. | 2.77% | 826,109 | $55.8M | Reduce -12.1% |
| AVTX Avalo Therapeutics Inc. | 2.66% | 2,900,000 | $53.6M | Add +116.3% |
| CYTK Cytokinetics Inc. | 2.33% | 550,000 | $46.9M | Reduce -21.5% |
| RVMD Revolution Medicines Inc. | 2.33% | 250,000 | $46.8M | Add +150.0% |
| ABVX Abivax SA-ADR | 2.19% | 330,000 | $44.0M | Reduce -18.5% |
| TRAX First Tracks Biotherapeutics | 2.03% | 2,032,012 | $40.9M | New |
| DNTH Dianthus Therapeutics Inc. | 1.94% | 400,000 | $39.0M | Add +14.3% |
| STRO Sutro Biopharma Inc. | 1.94% | 1,172,487 | $38.9M | Add +9.6% |
| NUVL Nuvalent Inc. Class A | 1.69% | 275,000 | $34.0M | Reduce -8.3% |
| TRVI Trevi Therapeutics Inc. | 1.67% | 1,800,172 | $33.6M | Reduce -10.0% |
| OVID Ovid Therapeutics Inc. | 1.36% | 10,144,562 | $27.3M | Reduce -4.6% |
| LXEO Lexeo Therapeutics Inc. | 1.34% | 5,807,611 | $27.0M | Add +15.0% |
| CLDX Celldex Therapeutics Inc. | 1.29% | 700,000 | $26.0M | Add +40.0% |
| BLTE Belite Bio Inc. - ADR | 1.26% | 165,000 | $25.4M | Add +153.8% |
| ELVN Enliven Therapeutics Inc. | 1.26% | 500,000 | $25.4M | Reduce -14.8% |
| FBRX Forte Biosciences Inc. | 1.21% | 1,145,391 | $24.3M | Add +13.2% |
| NRIX Nurix Therapeutics Inc. | 1.17% | 967,620 | $23.5M | No change |
| ANRO Alto Neuroscience Inc. | 1.12% | 850,000 | $22.4M | Add +70.0% |
| MDGL Madrigal Pharmaceuticals Inc. | 1.07% | 40,000 | $21.5M | Reduce -27.3% |
| PTGX Protagonist Therapeutics Inc. | 1.05% | 172,125 | $21.1M | No change |
| MLYS Mineralys Therapeutics Inc. | 1.01% | 750,000 | $20.2M | No change |
| RLAY Relay Therapeutics Inc. | 0.98% | 1,050,000 | $19.6M | Add +162.5% |
| SGMT Sagimet Biosciences Inc. Class A | 0.96% | 2,497,864 | $19.3M | Add +187.8% |
| JBIO Jade Biosciences Inc. | 0.93% | 840,350 | $18.7M | Add +31.3% |
| COGT Cogent Biosciences Inc. | 0.87% | 450,000 | $17.4M | Reduce -40.0% |
| TVTX Travere Therapeutics Inc. | 0.85% | 300,000 | $17.0M | No change |
| CGEM Cullinan Therapeutics Inc. | 0.79% | 875,760 | $15.9M | Add +12.1% |
| SVRA Savara Inc. | 0.77% | 2,512,153 | $15.5M | No change |
| IDYA Ideaya Biosciences Inc. | 0.74% | 400,000 | $14.9M | New |
| CATX Perspective Therapeutics Inc. | 0.71% | 4,214,582 | $14.4M | Add +33.2% |
| ODTX Odyssey Therapeutics Inc. | 0.71% | 766,346 | $14.3M | New |
| HLXC Helix Acquisition Corp. Class A | 0.66% | 1,250,000 | $13.3M | No change |
| EQ Equillium Inc. | 0.65% | 4,100,000 | $13.1M | Add +234.3% |
| ESTA Establishment Labs Holdings | 0.63% | 148,013 | $12.7M | Add +48.0% |
| CLYM Climb Bio Inc. | 0.63% | 972,000 | $12.7M | Add +38.9% |
| TEVA Teva Pharmaceutical-SP ADR | 0.63% | 374,000 | $12.7M | Reduce -73.3% |
| MANE Veradermics Inc. | 0.61% | 100,000 | $12.3M | Add +42.9% |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.61% | 150,000 | $12.2M | Reduce -25.0% |
| TSHA Taysha Gene Therapies Inc. | 0.59% | 1,750,000 | $11.9M | Add +75.0% |
| DMRA Damora Therapeutics Inc. | 0.55% | 425,000 | $11.1M | Reduce -5.6% |
| EPRX Eupraxia Pharmaceuticals Inc. | 0.54% | 1,650,000 | $10.9M | Add +3.8% |
| VERA Vera Therapeutics Inc. | 0.53% | 250,000 | $10.7M | No change |
| PRQR Proqr Therapeutics NV | 0.51% | 5,543,936 | $10.3M | Add +125.9% |
| NAMS Newamsterdam Pharma Co. NV | 0.46% | 275,000 | $9.3M | No change |
| KRRO Korro Bio Inc. | 0.46% | 706,904 | $9.3M | No change |
| AVR Anteris Technologies Global | 0.45% | 912,397 | $9.0M | No change |
| ZURA Zura Bio Ltd. | 0.43% | 1,464,303 | $8.6M | Reduce -42.9% |
| QURE Uniqure NV | 0.40% | 175,000 | $8.1M | New |
| ASND Ascendis Pharma A/S | 0.40% | 30,000 | $8.0M | Reduce -68.4% |
| IBIO Ibio Inc. | 0.35% | 4,007,881 | $7.0M | Add +29.0% |
| GENB Generate Biomedicines Inc. | 0.34% | 400,000 | $6.7M | Add +14.3% |
| TYRA Tyra Biosciences Inc. | 0.32% | 200,012 | $6.4M | Reduce -22.3% |
| SLGL Sol-Gel Technologies Ltd. | 0.31% | 84,900 | $6.3M | Add +142.6% |
| SABS Sab Biotherapeutics Inc. | 0.30% | 1,525,000 | $5.9M | Add +165.2% |
| MGNX Macrogenics Inc. | 0.28% | 1,216,606 | $5.6M | Add +143.3% |
| CRSP Crispr Therapeutics AG | 0.27% | 100,000 | $5.5M | Reduce -33.3% |
| ASMB Assembly Biosciences Inc. | 0.26% | 190,000 | $5.2M | New |
| RZLT Rezolute Inc. | 0.26% | 1,000,000 | $5.2M | Reduce -35.4% |
| DTIL Precision Biosciences Inc. | 0.25% | 646,576 | $5.1M | Add +8.1% |
| COAG Hemab Therapeutics Holdings | 0.25% | 138,030 | $5.1M | New |
| VRDN Viridian Therapeutics Inc. | 0.23% | 250,000 | $4.6M | No change |
| AVBP Arrivent Biopharma Inc. | 0.22% | 125,000 | $4.3M | Reduce -28.6% |
| VRCA Verrica Pharmaceuticals Inc. | 0.22% | 707,338 | $4.3M | No change |
| CMPS Compass Pathways PLC | 0.21% | 301,183 | $4.3M | Reduce -72.8% |
| MBX MBX Biosciences Inc. | 0.21% | 75,000 | $4.1M | Reduce -50.0% |
| RACC Research Alliance Corp. Class A | 0.20% | 370,000 | $4.0M | New |
| IMVT Immunovant Inc. | 0.19% | 100,000 | $3.9M | No change |
| AMAN Amanat Acquisition Corp. Class A | 0.19% | 375,000 | $3.8M | New |
| BHVN Biohaven Ltd. | 0.18% | 250,000 | $3.7M | New |
| FTH Faeth Therapeutics Inc. | 0.18% | 144,404 | $3.6M | New |
| KPTI Karyopharm Therapeutics Inc. | 0.15% | 312,500 | $3.1M | Reduce -37.5% |
| ALEC Alector Inc. | 0.15% | 1,510,000 | $3.0M | Add +202.0% |
| SGP Spyglass Pharma Inc. | 0.15% | 131,586 | $2.9M | Reduce -47.4% |
| CRNX Crinetics Pharmaceuticals Inc. | 0.14% | 75,000 | $2.8M | No change |
| OACCU Oaktree Acquisition III Life | 0.14% | 250,000 | $2.8M | No change |
| JATT Jatt II Acquisition Corp. | 0.11% | 200,000 | $2.3M | New |
| NMRA Neumora Therapeutics Inc. | 0.09% | 1,070,651 | $1.8M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 0.09% | 98,999 | $1.8M | New |
| ANL Adlai Nortye Group Ltd. | 0.09% | 153,847 | $1.8M | Reduce -6.6% |
| SPRB Spruce Biosciences Inc. | 0.08% | 30,000 | $1.6M | New |
| EIKN Eikon Therapeutics Inc. | 0.06% | 98,001 | $1.3M | New |
| OKUR Onkure Therapeutics Inc. Class A | 0.05% | 240,963 | $1.1M | No change |
| ENGN Engene Therapeutics Inc. | 0.05% | 600,000 | $1.0M | Reduce -1.7% |
| XFOR X4 Pharmaceuticals Inc. | 0.03% | 145,000 | $677K | No change |
| BOLD Boundless Bio Inc. | 0.03% | 250,000 | $625K | New |
| LENZ Lenz Therapeutics Inc. | 0.03% | 100,000 | $568K | No change |
| QTTB Q32 Bio Inc. | 0.02% | 27,777 | $354K | No change |
| OBIO Orchestra Biomed Holdings Inc. | 0.01% | 33,400 | $144K | Reduce -91.7% |
| NXTC Nextcure Inc. | 0.00% | 41,960 | $67K | Reduce -82.7% |
| ADGM Adagio Medical Holdings Inc. | 0.00% | 80,000 | $52K | No change |
Options reported separately and not counted above: MRNA puts ($35.0M), MRNA calls ($33.3M), ARKG calls ($31.5M), LLY calls ($24.0M), OMER puts ($13.4M), ALKS calls ($13.1M), QURE calls ($9.2M), EVMN puts ($6.6M), SMMT calls ($1.5M).
Other holdings (5): bonds, preferreds, convertibles and warrants · $33.5M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| COGENT BIOSCIENCES INC (COGT 1.625 11/15/31) | NOTE 1.625%11/1 · principal | 11,000,000 | $13.7M | Add +57.1% |
| OMEROS CORP (OMER 9.5 06/15/29) | NOTE 9.500% 6/1 · principal | 6,525,000 | $12.2M | No change |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 245,000 | $5.3M | No change |
| CELCUITY INC (CELC 0.25 08/01/32) | NOTE 0.250% 8/0 · principal | 2,000,000 | $2.3M | New |
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 75,000 | $278 | No change |
Total filed on the 13F, all lines: $2.0B.
Portfolio Sells Q1 2026 → Q2 2026
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −3.33 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −2.49 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -73.3% | 0.63% | −1.89 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −1.77 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -4.8% | 4.79% | −1.04 |
| ASND Ascendis Pharma A/S | Reduce -68.4% | 0.40% | −0.90 |
| COGT Cogent Biosciences Inc. | Reduce -40.0% | 0.87% | −0.86 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −0.67 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -27.3% | 1.07% | −0.66 |
| WVE Wave Life Sciences Ltd. | Sold out | 0.00% | −0.61 |
| ABVX Abivax SA-ADR | Reduce -18.5% | 2.19% | −0.51 |
| ZURA Zura Bio Ltd. | Reduce -42.9% | 0.43% | −0.48 |
| CYTK Cytokinetics Inc. | Reduce -21.5% | 2.33% | −0.43 |
| ERAS Erasca Inc. | Reduce -1.9% | 4.78% | −0.40 |
| ANAB Anaptysbio Inc. | Reduce -12.1% | 2.77% | −0.35 |
| TYRA Tyra Biosciences Inc. | Reduce -22.3% | 0.32% | −0.27 |
| SGP Spyglass Pharma Inc. | Reduce -47.4% | 0.15% | −0.24 |
| ENGN Engene Therapeutics Inc. | Reduce -1.7% | 0.05% | −0.20 |
| CRSP Crispr Therapeutics AG | Reduce -33.3% | 0.27% | −0.16 |
| CMPS Compass Pathways PLC | Reduce -72.8% | 0.21% | −0.15 |
| NXTC Nextcure Inc. | Reduce -82.7% | 0.00% | −0.15 |
| NUVL Nuvalent Inc. Class A | Reduce -8.3% | 1.69% | −0.15 |
| DMRA Damora Therapeutics Inc. | Reduce -5.6% | 0.55% | −0.15 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -25.0% | 0.61% | −0.14 |
| CORT Corcept Therapeutics Inc. | Sold out | 0.00% | −0.12 |
| ELVN Enliven Therapeutics Inc. | Reduce -14.8% | 1.26% | −0.12 |
| KZR Kezar Life Sciences Inc. | Sold out | 0.00% | −0.10 |
| OBIO Orchestra Biomed Holdings Inc. | Reduce -91.7% | 0.01% | −0.10 |
| MBX MBX Biosciences Inc. | Reduce -50.0% | 0.21% | −0.06 |
| OVID Ovid Therapeutics Inc. | Reduce -4.6% | 1.36% | −0.06 |
| AVBP Arrivent Biopharma Inc. | Reduce -28.6% | 0.22% | −0.03 |
| RZLT Rezolute Inc. | Reduce -35.4% | 0.26% | −0.02 |
| KPTI Karyopharm Therapeutics Inc. | Reduce -37.5% | 0.15% | −0.01 |
| ANL Adlai Nortye Group Ltd. | Reduce -6.6% | 0.09% | +0.02 |
| APGE Apogee Therapeutics Inc. | Reduce -23.2% | 6.51% | +0.04 |
| ALKS Alkermes PLC | Reduce -16.7% | 2.93% | +0.07 |
| TRVI Trevi Therapeutics Inc. | Reduce -10.0% | 1.67% | +0.24 |
Portfolio Buys Q1 2026 → Q2 2026
| TRAX First Tracks Biotherapeutics | New | 2.03% | +2.03 |
| ROIV Roivant Sciences Ltd. | Add +33.9% | 6.60% | +1.96 |
| RVMD Revolution Medicines Inc. | Add +150.0% | 2.33% | +1.75 |
| AVTX Avalo Therapeutics Inc. | Add +116.3% | 2.66% | +1.47 |
| ORKA Oruka Therapeutics Inc. | Add +18.1% | 2.79% | +1.32 |
| IDYA Ideaya Biosciences Inc. | New | 0.74% | +0.74 |
| RLAY Relay Therapeutics Inc. | Add +162.5% | 0.98% | +0.74 |
| ODTX Odyssey Therapeutics Inc. | New | 0.71% | +0.71 |
| SGMT Sagimet Biosciences Inc. Class A | Add +187.8% | 0.96% | +0.69 |
| BLTE Belite Bio Inc. - ADR | Add +153.8% | 1.26% | +0.64 |
| EQ Equillium Inc. | Add +234.3% | 0.65% | +0.51 |
| ANRO Alto Neuroscience Inc. | Add +70.0% | 1.12% | +0.44 |
| QURE Uniqure NV | New | 0.40% | +0.40 |
| JBIO Jade Biosciences Inc. | Add +31.3% | 0.93% | +0.39 |
| MANE Veradermics Inc. | Add +42.9% | 0.61% | +0.35 |
| CLDX Celldex Therapeutics Inc. | Add +40.0% | 1.29% | +0.35 |
| CLYM Climb Bio Inc. | Add +38.9% | 0.63% | +0.34 |
| STRO Sutro Biopharma Inc. | Add +9.6% | 1.94% | +0.34 |
| TSHA Taysha Gene Therapies Inc. | Add +75.0% | 0.59% | +0.33 |
| ESTA Establishment Labs Holdings | Add +48.0% | 0.63% | +0.29 |
| PRQR Proqr Therapeutics NV | Add +125.9% | 0.51% | +0.27 |
| ASMB Assembly Biosciences Inc. | New | 0.26% | +0.26 |
| COAG Hemab Therapeutics Holdings | New | 0.25% | +0.25 |
| RACC Research Alliance Corp. Class A | New | 0.20% | +0.20 |
| MGNX Macrogenics Inc. | Add +143.3% | 0.28% | +0.19 |
| AMAN Amanat Acquisition Corp. Class A | New | 0.19% | +0.19 |
| BHVN Biohaven Ltd. | New | 0.18% | +0.18 |
| DNTH Dianthus Therapeutics Inc. | Add +14.3% | 1.94% | +0.18 |
| FTH Faeth Therapeutics Inc. | New | 0.18% | +0.18 |
| SABS Sab Biotherapeutics Inc. | Add +165.2% | 0.30% | +0.16 |
| SLGL Sol-Gel Technologies Ltd. | Add +142.6% | 0.31% | +0.15 |
| CGEM Cullinan Therapeutics Inc. | Add +12.1% | 0.79% | +0.13 |
| JATT Jatt II Acquisition Corp. | New | 0.11% | +0.11 |
| NMRA Neumora Therapeutics Inc. | New | 0.09% | +0.09 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 0.09% | +0.09 |
| ALEC Alector Inc. | Add +202.0% | 0.15% | +0.09 |
| SPRB Spruce Biosciences Inc. | New | 0.08% | +0.08 |
| GENB Generate Biomedicines Inc. | Add +14.3% | 0.34% | +0.07 |
| EIKN Eikon Therapeutics Inc. | New | 0.06% | +0.06 |
| DTIL Precision Biosciences Inc. | Add +8.1% | 0.25% | +0.06 |
| BOLD Boundless Bio Inc. | New | 0.03% | +0.03 |
| IBIO Ibio Inc. | Add +29.0% | 0.35% | −0.00 |
| CATX Perspective Therapeutics Inc. | Add +33.2% | 0.71% | −0.08 |
| EPRX Eupraxia Pharmaceuticals Inc. | Add +3.8% | 0.54% | −0.15 |
| PRAX Praxis Precision Medicines I | Add +8.8% | 3.08% | −0.20 |
| FBRX Forte Biosciences Inc. | Add +13.2% | 1.21% | −0.36 |
| LXEO Lexeo Therapeutics Inc. | Add +15.0% | 1.34% | −0.39 |
| INSM Insmed Inc. | Add +35.4% | 3.45% | −1.25 |
Options Activity Q1 2026 → Q2 2026
| SPY SS SPDR S&P 500 ETF Trust-US | put | Sold out | 200,000 | $130.1Mbefore exit |
| MRNA Moderna Inc. | put | New | 500,000 | $35.0M |
| MRNA Moderna Inc. | call | Reduce -40.6% | 475,000 | $33.3M |
| ARKG ARK Genomic Revolution ETF | call | New | 750,000 | $31.5M |
| LLY Eli Lilly & Co. | call | New | 20,000 | $24.0M |
| BMY Bristol-Myers Squibb Co. | call | Sold out | 300,000 | $18.2Mbefore exit |
| OMER Omeros Corp. | put | New | 1,411,300 | $13.4M |
| ALKS Alkermes PLC | call | New | 250,000 | $13.1M |
| RVMD Revolution Medicines Inc. | put | Sold out | 100,000 | $9.7Mbefore exit |
| IBRX Immunitybio Inc. | put | Sold out | 1,250,000 | $9.6Mbefore exit |
| QURE Uniqure NV | call | Reduce -33.3% | 200,000 | $9.2M |
| EVMN Evommune Inc. | put | New | 500,100 | $6.6M |
| NVO Novo-Nordisk A/S-Spons ADR | call | Sold out | 175,000 | $6.4Mbefore exit |
| DNTH Dianthus Therapeutics Inc. | call | Sold out | 50,000 | $4.2Mbefore exit |
| CGON CG Oncology Inc. | call | Sold out | 60,000 | $4.1Mbefore exit |
| CELC Celcuity Inc. | call | Sold out | 30,000 | $3.4Mbefore exit |
| SMMT Summit Therapeutics Inc. | call | New | 100,000 | $1.5M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q1 2026 → Q2 2026
| COGENT BIOSCIENCES INC (COGT 1.625 11/15/31) | NOTE 1.625%11/1 · principal | Add +57.1% | 11,000,000 | $13.7M |
| CELCUITY INC (CELC 2.75 08/01/31) | NOTE 2.750% 8/0 · principal | Sold out | 3,000,000 | $7.3Mbefore exit |
| CELCUITY INC (CELC 0.25 08/01/32) | NOTE 0.250% 8/0 · principal | New | 2,000,000 | $2.3M |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $2.0B | ROIV, APGE, SYRE, XENE, ERAS |
| Q1 2026 | 90 | $1.7B | APGE, XENE, ERAS, INSM, ROIV |
| Q4 2025 | 80 | $1.3B | APGE, INSM, ABVX, VTYX, XENE |
| Q3 2025 | 80 | $1.0B | VRNA, INSM, SPY, XENE, MDGL |
| Q2 2025 | 71 | $648.9M | VRNA, INSM, XENE, ACLX, BPMC |
| Q1 2025 | 75 | $603.1M | XENE, APGE, VRNA, ACLX, ALKS |
| Q4 2024 | 68 | $588.3M | XENE, APGE, ACLX, ALKS, TEVA |
| Q3 2024 | 70 | $601.0M | XENE, APGE, NUVL, ACLX, ALKS |
| Q2 2024 | 78 | $576.0M | XENE, APGE, MDGL, ACLX, TEVA |
| Q1 2024 | 69 | $571.1M | APGE, XENE, MDGL, CRNX, AUTL |